Merkel Cell Carcinoma at a Site of Vaccination

B. Monteagudo,* M. Cabanillas,* J.A. García-Rego, and J.M. Cacharrón*

*Servicio de Dermatología, *Servicio de Anatomía Patológica, Complejo Hospitalario Arcángel Reyes, Ferrol, A Coruña, Spain

To the Editor:

Adverse skin reactions from vaccination are very varied and can be local or generalized. Immediately after immunization, erythema, edema, pain, and induration may occur exclusively on the site of the injection, and these disappear spontaneously. Less frequently, papules or nodules appear exclusively on the site of the injection, and these disappear spontaneously. Various tumors have also been described on the site of vaccine injections: basal cell carcinoma, squamous cell carcinoma, malignant melanoma, malignant fibrous histiocytoma, dermatofibrosarcoma protuberans (including the pigmented variant, Bednar tumor), dermatofibroma, and marginal zone B-cell lymphoma. The delay between vaccination and the appearance of the tumor varies widely, from days in the case of lymphomas, to more than 30 years in many patients with basal cell carcinoma. 1,2

In this letter we report the case of an 84-year-old man who consulted with a tumor on the right arm that appeared a week after receiving an influenza vaccination in the same location. Histopathological and immunohistochemical studies provided the basis for a diagnosis of Merkel cell carcinoma (MCC).

The patient was an 84-year-old man with a history of Parkinson disease, referred to the Dermatology Department because of a fast-growing asymptomatic lesion in the right deltoid region present for 2 months. According to the patient and his family, the lesion first appeared on the site of the influenza vaccination received a week previously during the 2007 vaccination campaign (trivalent vaccine of inactive and fractionated viruses containing the following antigens: A/Solomon Islands/3/2006 [H1N1]-like strain, A/Wisconsin/67/2005 [H3N2]-like strain, and B/Malaysia/2506/2004-like strain). His physician initially diagnosed an abscess caused by administration of the vaccine, and prescribed oral antibiotics prior to draining. Examination revealed a hard and poorly defined tumor, measuring 5 cm × 3 cm, located on the external surface of the right arm. The tumor surface showed many violaceous dome-shaped nodules (Figure).

A biopsy was taken to confirm a provisional diagnosis of pseudolymphoma or lymphoma caused by the vaccination and the ensuing histopathological study showed a tumoral infiltration of the dermis by rounded monomorphic cells of medium size with scant cytoplasm, round nuclei, and small nucleoli, forming solid masses or small trabecular structures. The mitotic index was high. Immunohistochemical study proved positive for cytokeratin 20, neuronal specific enolase, chromogranin A, and chromogranin B. There was no immunoreactivity to protein S-100, leukocyte common antigen, CD20, CD3, cytokeratin 7, or thyroid transcription factor 1. A diagnosis of MCC was made and the patient was referred to the Oncology Department.

MCC—first described by Toker in 1972—is a rare malignant cutaneous tumor of neuroendocrine origin with poor prognosis and rapid progression. It tends to present as a fast-growing nodular erythematous lesion on the head, neck, or limbs in people aged over 65 years. 3,4

The pathogenesis is unknown although various factors have been implicated: a) ultraviolet radiation—a greater
In conclusion, we present a case of MCC located at a site of vaccination. As we have encountered no similar cases in the literature to date—even though the target population for anti-influenza vaccination overlaps extensively with those at greater risk of developing MCC (individuals aged 65 years or older and immunodepressed patients)—we believe this is a case of simple coincidence. However, the close temporal relationship could indicate that vaccination causes a local immune alteration through an unknown pathogenic mechanism that would facilitate the development of MCC patients with a predisposition to the disease.

Correspondence:
Benigno Monteaegudo Sánchez
C/Alegre, 83-85, 3.º A
15401 Ferrol, A Coruña, Spain
benims@hotmail.com

Conflicts of Interest
The authors declare no conflicts of interest.

References

Eruptive Clear Cell Acanthoma

V. Morillo,a P. Manrique,a I. Zabalza,b and J.L. Artolaa

To the Editor:
Clear cell acanthoma (CCA) was described by Degos et al in 1962. They suggested that this was a benign epithelial tumor of epidermal origin rather than a reactive hyperplasia of inflammatory origin, although they questioned this affirmation 8 years later. In recent years, several authors have vindicated the inflammatory nature of this lesion, and a number of writers view the condition as a localized form of psoriasis.2,3

Eruptive Clear Cell Acanthoma

V. Morillo,a P. Manrique,a I. Zabalza,b and J.L. Artolaa

To the Editor:
Clear cell acanthoma (CCA) was described by Degos et al in 1962. They suggested that this was a benign epithelial tumor of epidermal origin rather than a reactive hyperplasia of inflammatory origin, although they questioned this affirmation 8 years later. In recent years, several authors have vindicated the inflammatory nature of this lesion, and a number of writers view the condition as a localized form of psoriasis.2,3